People

Mei-Yin Chen Polley, PhD

Dr. Polley’s primary research involves the design, conduct, and analysis of all phases of cancer clinical trials. She is the Senior Statistician of the Brain Tumor Committee for NRG Oncology, a National Cancer Institute sponsored member of the national clinical trials network group. Previously, she served as the Director of the Biostatistics and Bioinformatics Core of the Mayo Clinic Breast Cancer Specialized Program of Research Excellence (SPORE). Dr. Polley had served on many scientific governing or advisory bodies including the National Cancer Institute Steering Committees (breast, lymphoma, head and neck cancer, and pediatric and adolescent solid tumor), the Scientific Program Committee of American Society of Clinical Oncology (ASCO) annual meetings, and the US Veterans Affairs (VA) Oncology A Study Section. Dr. Polley’s methodological interests include early-phase clinical trial designs, biomarker reproducibility, innovative group sequential methods for biomarker validation, prognostic and predictive modeling, design and analysis of biomarker-based clinical trials, and design and monitoring of late phase clinical trials.

Columbia University
New York, New York
PhD - Biostatistics
2006

Columbia University
New York, New York
MS - Biostatistics
2001

Harvard University
Cambridge, Massachusetts
MA - Statistics
1999

A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab.
Korpics MC, Polley MY, Bhave SR, Redler G, Pitroda SP, Luke JJ, Chmura SJ. A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab. Int J Radiat Oncol Biol Phys. 2020 Sep 01; 108(1):189-195.
PMID: 32569799

Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial.
Schöder H, Polley MC, Knopp MV, Hall N, Kostakoglu L, Zhang J, Higley HR, Kelloff G, Liu H, Zelenetz AD, Cheson BD, Wagner-Johnston N, Kahl BS, Friedberg JW, Hsi ED, Leonard JP, Schwartz LH, Wilson WH, Bartlett NL. Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood. 2020 Jun 18; 135(25):2224-2234.
PMID: 32232481

The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias.
Baughn LB, Li Z, Pearce K, Vachon CM, Polley MY, Keats J, Elhaik E, Baird M, Therneau T, Cerhan JR, Bergsagel PL, Dispenzieri A, Rajkumar SV, Asmann YW, Kumar S. The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias. Blood Cancer J. 2020 03 16; 10(3):39.
PMID: 32179748

Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients.
Norton N, Youssef B, Hillman DW, Nassar A, Geiger XJ, Necela BM, Liu H, Ruddy KJ, Polley MC, Ingle JN, Couch FJ, Perez EA, Liu MC, Carter JM, Leon-Ferre RA, Boughey JC, Somers EB, Kalari KR, Visscher DW, Goetz MP, Knutson KL. Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. NPJ Breast Cancer. 2020; 6:4.
PMID: 32047850

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer.
Page DB, Bear H, Prabhakaran S, Gatti-Mays ME, Thomas A, Cobain E, McArthur H, Balko JM, Gameiro SR, Nanda R, Gulley JL, Kalinsky K, White J, Litton J, Chmura SJ, Polley MY, Vincent B, Cescon DW, Disis ML, Sparano JA, Mittendorf EA, Adams S. Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. NPJ Breast Cancer. 2019; 5:34.
PMID: 31602395

Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era.
Taparra K, Liu H, Polley MY, Ristow K, Habermann TM, Ansell SM. Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era. Leuk Lymphoma. 2020 02; 61(2):298-308.
PMID: 31517559

Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.
Muss HB, Polley MC, Berry DA, Liu H, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Kartcheske PA, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Sutton LM, Magrinat G, Parker BA, Hart RD, Grenier D, Hurria A, Jatoi A, Norton L, Hudis CA, Winer EP, Carey L. Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. J Clin Oncol. 2019 09 10; 37(26):2338-2348.
PMID: 31339827

Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).
Blum KA, Polley MY, Jung SH, Dockter TJ, Anderson S, Hsi ED, Wagner-Johnston N, Christian B, Atkins J, Cheson BD, Leonard JP, Bartlett NL. Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance). Cancer. 2019 10 01; 125(19):3378-3389.
PMID: 31174236

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schöder H, Zelenetz AD, Leonard JP. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019 07 20; 37(21):1790-1799.
PMID: 30939090

Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations.
Peterson JF, Rowsey RA, Marcou CA, Pearce KE, Williamson CM, Frederick LA, Greipp PT, Ketterling RP, Kumar S, Viswanatha DS, Polley MY, Fink JM, Reichard KK, Van Dyke DL, Baughn LB. Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations. Blood Cancer J. 2019 02 19; 9(3):20.
PMID: 30783078

View All Publications

Breast Cancer Specialized Program of Research Excellence - Developmental Research Program Award
Mayo Clinic
2018

The Fraternal Order of Eagles Cancer Research Award
Mayo Clinic Cancer Center
2017

Distinguished Achievement Award
Kelly Government Solutions, National Cancer Institute
2012

Award for Excellence in Clinical Research
The American Brain Tumor Association
2009

REAC Pilot Research Award in Basic and Clinical/Translational Sciences
University of California San Francisco
2009

Travel Award - Biostatistics Workshop
American Association for Cancer Research (AACR)
2008

The Joseph L. Fleiss Memorial Prize in Biostatistics for an Outstanding Dissertation
Columbia University
2006

Merck & Co., Inc. Fellowship
Columbia University
2001 - 2004